Intraperitoneal administration of nanoparticles containing tocopheryl succinate prevents peritoneal dissemination

Area of Science:

• Nanomedicine
• Oncology
• Biotechnology

Background:

• Peritoneal dissemination of colon cancer is a major challenge.
• Nanoparticle instability in vivo limits efficacy for abdominal cancer treatment.
• Tocopheryl succinate nanoparticles offer enhanced in vivo stability and anticancer properties.

Purpose of the Study:

• To evaluate the efficacy of tocopheryl succinate nanoparticles for preventing colon cancer peritoneal dissemination.
• To assess the biodistribution and retention of tocopheryl succinate nanoparticles after intraperitoneal administration.
• To elucidate the mechanisms underlying the anticancer effects of these nanoparticles.

Main Methods:

• Development of tocopheryl succinate nanoparticles.
• Intraperitoneal administration in a colon cancer dissemination model in mice.
• Biodistribution studies using quantum dot-labeled nanoparticles and ICP-MS.
• Assessment of tumor growth, cancer cell proliferation, and key cytokine/macrophage markers.

Main Results:

• Intraperitoneal administration of tocopheryl succinate nanoparticles significantly prevented peritoneal dissemination.
• These nanoparticles exhibited prolonged retention in the abdominal cavity compared to intravenous administration.
• Anticancer effects included inhibition of cancer cell proliferation and modulation of the tumor microenvironment (reduced VEGF-A, IL-10, M2 TAMs).

Conclusions:

• Tocopheryl succinate nanoparticles are a promising strategy for preventing colon cancer peritoneal dissemination.
• Intraperitoneal delivery ensures sustained local drug exposure and enhanced therapeutic outcomes.
• The nanoparticles exert multifaceted antitumor effects by directly targeting cancer cells and remodeling the peritoneal microenvironment.